Drugs / OPB-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07030907 | Jun 2025 → May 2028 expected | ovarian carcinoma, refractory malignant neoplasm | Outpace Bio, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-05 | Outpace Bio, Inc. | Results Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting outpacebio.com ↗
In vivo tumor re-implant and CAR T serial transfer studies further demonstrate long-lived functional persistence, anti-tumor activity, and maintenance of stem and memory function in the OPB-101 cell product even after sustained anti-tumor activity in stringent xenograft mouse models. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-05 | Outpace Bio, Inc. | Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting outpacebio.com ↗ |
| 2024-04-07 | Outpace Bio, Inc. | OPB-101: An optimized mesothelin-specific CAR T cell product expressing CD8-targeted IL-2/15 and engineered to resist T cell exhaustion outpacebio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07030907 ↗ |